Neoadjuvant PD-1 Blockade in Resectable Merkel Cell Carcinoma
Status:
Not yet recruiting
Trial end date:
2026-09-30
Target enrollment:
Participant gender:
Summary
The main purpose of this study is to determine the response of Merkel cell carcinoma to
pembrolizumab before surgery and to determine whether it further reduces the risk for disease
recurrence. Another purpose of this study is to look at the side effects that occur when the
experimental drug pembrolizumab is given to people with Merkel cell carcinoma before and
after their standard of care surgery to remove the Merkel cell carcinoma.
Phase:
Phase 2
Details
Lead Sponsor:
Abramson Cancer Center of the University of Pennsylvania